[The effect of tularemia live vaccine on contrasuppression of lymphocytes in patients with cancer of the corpus uteri during combined therapy and long term].

A significant decrease in the percentage of women showing contrasuppression of blood lymphocytes, as compared with control, was identified (p < 0.1); it was particularly low at terminal stages (III-IV). Surgery and subsequent radiotherapy were followed by further inhibition, particularly in terminally-ill patients.

[Adjuvant immunotherapy for patients with cancer of corpus uteri].

A randomized study was carried out of the efficacy of a new procedure of adjuvant immunotherapy for cancer of corpus uteri in conjunction with anticoagulant treatment. Ninety-seven patients (76-stage I-II and 21-stage III-IV) were inoculated tularemia booster (TB) and received fibrinolysin, pelentan and aspirin 15-20 days before combined treatment including uterine extirpation or extirpation with adnexa followed by telegammatherapy. Two groups of identical numbers of patients with an identical distribution of tumor progression stage were used as controls.

[Evaluation of immunotherapy in breast cancer (stage III-IV) and in cancer of the corpus uteri (stage I-III)].

A new clinically-tested procedure of adjuvant immunotherapy carried out in conjunction with anticoagulant treatment is discussed. Application of said method has significantly improved the short-term and end results of treatment of inoperable cases of breast cancer, stage III-IV, receiving chemotherapy and patients with cancer of corpus uteri, stage I-III, receiving combined therapy plus radiation.